VK2735 for Weight Management Phase 2 (Venture Oral Dosing)
← catalyst calendarSponsored by Viking Therapeutics, Inc. (industry) · VKTX — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
280actual
Sites
15
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-18 | actual | When the study began enrolling |
| Primary completion | 2025-06-24 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-15 | actual | The whole study's end, after follow-up |
| First posted | 2025-02-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Weight Loss
Interventions
- Drug: Placebo
- Drug: VK2735
Primary outcome
what the primary-completion date above is the date OFPercent (relative) change from baseline in body weight after 13 weeks of treatment
measured 13 Weeks
Permalink · VKTX's whole pipeline · Catalyst calendar · Every registered study · What changed